13D Filing: OrbiMed Advisors and Rhythm Pharmaceuticals Inc (RYTM)

Page 2 of 14

Page 2 of 14 – SEC Filing

CUSIP No. 76243J105
1
NAME OF REPORTING PERSON

OrbiMed Advisors LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
(b)
3
SEC USE ONLY
4
SOURCE OF FUNDS

AF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
6
CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
NUMBER OF SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
2,901,295
9
SOLE DISPOSITIVE POWER
0
10
SHARED DISPOSITIVE POWER
2,901,295
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,901,295
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.7% (1)
14
TYPE OF REPORTING PERSON (See Instructions)

IA
(1)
This percentage is calculated based upon 27,131,484 outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Rhythm Pharmaceuticals, Inc. (the “Issuer”), as set forth in the Issuer’s Form 424B4, filed with the Securities and Exchange Commission on October 5, 2017.

Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)

Page 2 of 14